Literature DB >> 240023

Potential histamine H2-receptor antagonists. 2. N-alpha-Guanylhistamine.

G J Durant, M E Parsons, J W Black.   

Abstract

The agonist molecule, histamine, has been used as a starting point for the design of potential H2-receptor antagonists. Converting the side-chain amino group into a guanidine yielded the first histamine H2-receptor antagonist, Nalpha-guanylhistamine. Antagonism of H2 receptors was demonstrated by the inhibition of histamine-stimulated gastric acid secretion in the rat at high dose levels (approximate ID50 800 MUmol/kg, iv) and by the inhibition of histamine-stimulated tachycardia of guinea-pig right atrium (pA2 equals 3.9). Guanylhistamine behaves as a partial agonist at histamine H2 receptors.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 240023     DOI: 10.1021/jm00242a014

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Personal reflections on Sir James Black (1924-2010) and histamine.

Authors:  C Robin Ganellin
Journal:  Inflamm Res       Date:  2010-10-27       Impact factor: 4.575

2.  Dimaprit -(S-[3-(N,N-dimethylamino)prophyl]isothiourea) - a highly specific histamine H2 -receptor agonist. Part 1. Pharmacology.

Authors:  M E Parsons; D A Owen; C R Ganellin; G J Durant
Journal:  Agents Actions       Date:  1977-03

3.  Antagonism of histamine-activated adenylate cyclase in brain by D-lysergic acid diethylamide.

Authors:  J P Green; C L Johnson; H Weinstein; S Maayani
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

4.  Dimaprit--[S-[3-(N,N-dimethylamino)propyl]isothiourea]--a highly specific histamine H2-receptor agonist. Part 1. Pharmacology. 1977.

Authors:  M E Parsons; D A Owen; C R Ganellin; G J Durant
Journal:  Agents Actions       Date:  1994-12

5.  The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects.

Authors:  A M Molloy; J Ardill; G H Tomkin
Journal:  Diabetologia       Date:  1980-08       Impact factor: 10.122

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.